Carley G. Hendriks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carley G. Hendriks has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Emel Alpay
Mammoth Biosciences, Inc., 1000 Marina Blvd, Suite 600, Brisbane, CA 94005, USA
2 shared publications - James P. Broughton
Division of Biology, University of California, San Diego, La Jolla, CA 92093-0349, USA
2 shared publications - Janice S. Chen
Mammoth Biosciences, Inc., 1000 Marina Blvd, Suite 600, Brisbane, CA 94005, USA
2 shared publications Adam L. Garske
Mammoth Biosciences, Inc., 1000 Marina Blvd, Suite 600, Brisbane, CA 94005, USA
1 shared publicationBenjamin A. Blizard
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication- Bridget McKay
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication
Latest Publications
- Open Access
MB-CasFire™: A Plug-and-Play, Thermostable CRISPR Enzyme for Precise Nucleic Acid Detection
CRISPR-based detection technologies have the potential to enable precise, rapid, and cost-effective diagnostic and biosurveillance solutions by pairing sensitive and specific nucleic acid detection with a simple workflow. Combining isothermal amplification and CRISPR detection in a single reaction as a “one-pot” detection method can meet these needs, but only if the CRISPR enzyme remains active at the temperatures and salt concentrations that isothermal amplification requires. Here we describe MB-CasFire™, a CRISPR-Cas enzyme engineered from a naturally thermostable Cas12a for improved stability and performance, as a “plug-and-play” DETECTR ® (DNA Endonuclease-Targeted CRISPR Trans Reporter) enzyme for sensitive and specific nucleic acid detection. MB-CasFire remains active at elevated temperatures in amplification buffers and supports one-pot detection with loop-mediated isothermal amplification (LAMP) and nicking enzyme amplification reaction (NEAR), eliminating transfers between amplification and readout, and increasing the signal-to-noise to enable precise nucleic acid detection. This method, called OnePot DETECTR, is also compatible with commercially available isothermal master mixes, including those from New England Biolabs, allowing assays to be assembled from standard reagents. Using MB-CasFire, we detected SARS-CoV-2 in nasal swab samples with a LAMP-based OnePot DETECTR assay and Neisseria gonorrhoeae in urine samples with a NEAR-based OnePot DETECTR assay. MB-CasFire also functioned in multiplex detection and single-nucleotide polymorphism discrimination assays for antibiotic resistance genotyping. These results support MB-CasFire as a versatile detection enzyme that simplifies assay architecture for CRISPR-based detection assays that amplify, recognize, and report the presence of nucleic acid targets in a single reaction without thermocycling.
Open AccessMB-CasFire™: A Plug-and-Play, Thermostable CRISPR Enzyme for Precise Nucleic Acid Detection
CRISPR-based detection technologies have the potential to enable precise, rapid, and cost-effective diagnostic and biosurveillance solutions by pairing sensitive and specific nucleic acid detection with a simple workflow. Combining isothermal amplification and CRISPR detection in a single reaction as a “one-pot” detection method can meet these needs, but only if the CRISPR enzyme remains active at the temperatures and salt concentrations that isothermal amplification requires. Here we describe MB-CasFire™, a CRISPR-Cas enzyme engineered from a naturally thermostable Cas12a for improved stability and performance, as a “plug-and-play” DETECTR ® (DNA Endonuclease-Targeted CRISPR Trans Reporter) enzyme for sensitive and specific nucleic acid detection. MB-CasFire remains active at elevated temperatures in amplification buffers and supports one-pot detection with loop-mediated isothermal amplification (LAMP) and nicking enzyme amplification reaction (NEAR), eliminating transfers between amplification and readout, and increasing the signal-to-noise to enable precise nucleic acid detection. This method, called OnePot DETECTR, is also compatible with commercially available isothermal master mixes, including those from New England Biolabs, allowing assays to be assembled from standard reagents. Using MB-CasFire, we detected SARS-CoV-2 in nasal swab samples with a LAMP-based OnePot DETECTR assay and Neisseria gonorrhoeae in urine samples with a NEAR-based OnePot DETECTR assay. MB-CasFire also functioned in multiplex detection and single-nucleotide polymorphism discrimination assays for antibiotic resistance genotyping. These results support MB-CasFire as a versatile detection enzyme that simplifies assay architecture for CRISPR-based detection assays that amplify, recognize, and report the presence of nucleic acid targets in a single reaction without thermocycling.
- Open Access
- 10 September 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (7) , 2100304
CRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
The programmable nature of sequence‐specific targeting by CRISPR‐Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross‐disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID‐19 pandemic. We further discuss the advances and potential for CRISPR‐based detection to have an impact across a continuum of diagnostic applications.
- 10 September 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (7) , 2100304
Open AccessCRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
The programmable nature of sequence‐specific targeting by CRISPR‐Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross‐disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID‐19 pandemic. We further discuss the advances and potential for CRISPR‐based detection to have an impact across a continuum of diagnostic applications.